Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After Trial Failure – MedCity News
Gilead Sciences’ Trodelvy did not meet the main overall survival goal of its confirmatory Phase 3 test. The antibody drug conjugate was awarded accelerated approval for advanced urothelial carcinoma in 2021.